Expression of prostate stem cell antigen (PSCA) in prostate cancer: A tissue microarray study of Iranian patients

Pathology Research and Practice

Volumn 210, Issue 1, 2014, Pages 18-23

  Taeb, Jaleh ^a   Asgari, Mojgan ^a,b   Abolhasani, Maryam ^a,b   Farajollahi, Mohammad M ^a   Madjd, Zahra ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diagnosis; Prostate cancer; PSCA; Tissue microarray

Indexed keywords

PROSTATE STEM CELL ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; VERY ELDERLY;

DIAGNOSIS; PROSTATE CANCER; PSCA; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IRAN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891482852     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.09.012     Document Type: Article

References (34)

1. Asgari M., Morakabati A. Estrogen receptor beta expression in prostate adenocarcinoma. Diagn. Pathol. 2011, 6:61.
2. Haas G.P., Delongchamps N., Brawley O.W., Wang C.Y., de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can. J. Urol. 2008, 15:3866-3871.
3. Akbari M.E., Hosseini S.J., Rezaee A., Hosseini M.M., Rezaee I., Sheikhvatan M. Incidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005. Asian Pac. J. Cancer Prev. 2008, 9:549-552.
4. Farahmand M., Khademolhosseini F., Mehrabani D. Trend of prostate cancer in Fars Province, Southern Iran, 2001-2007. J. Res. Med. Sci. 2011, 15:295-297.
5. Hosseini M., SeyedAlinaghi S., Mahmoudi M., McFarland W. A case-control study of risk factors for prostate cancer in Iran. Acta Med. Iran. 2010, 48:61-66.
6. Mousavi S.M. Toward prostate cancer early detection in Iran. Asian Pac. J. Cancer Prev. 2009, 10:413-418.
7. Mousavi S.M., Gouya M.M., Ramazani R., Davanlou M., Hajsadeghi N., Seddighi Z. Cancer incidence and mortality in Iran. Ann. Oncol. 2009, 20:556-563.
8. Pourmand G., Salem S., Mehrsai A., Lotfi M., Amirzargar M.A., Mazdak H., Roshani A., Kheirollahi A., Kalantar E., Baradaran N., Saboury B., Allameh F., Karami A., Ahmadi H., Jahani Y. The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pac. J. Cancer Prev. 2007, 8:422-428.
9. Raff A.B., Gray A., Kast W.M. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett. 2009, 277:126-132.
10. Saffran D.C., Raitano A.B., Hubert R.S., Witte O.N., Reiter R.E., Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:2658-2663.
11. Reiter R.E., Gu Z., Watabe T., Thomas G., Szigeti K., Davis E., Wahl M., Nisitani S., Yamashiro J., Le Beau M.M., Loda M., Witte O.N. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1735-1740.
12. Saeki N., Gu J., Yoshida T., Wu X. Prostate stem cell antigen (PSCA): a Jekyll and Hyde molecule?. Clin. Cancer Res. 2010, 16:3533-3538.
13. Reiter R.E., Sato I., Thomas G., Qian J., Gu Z., Watabe T., Loda M., Jenkins R.B. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes. Chromosomes Cancer 2000, 27:95-103.
14. Ross S., Spencer S.D., Lasky L.A., Koeppen H. Selective expression of murine prostate stem cell antigen in fetal and adult tissues and the transgenic adenocarcinoma of the mouse prostate model of prostate carcinogenesis. Am. J. Pathol. 2001, 158:809-816.
15. Gu Z., Thomas G., Yamashiro J., Shintaku I.P., Dorey F., Raitano A., Witte O.N., Said J.W., Loda M., Reiter R.E. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19:1288-1296.
16. Han K.R., Seligson D.B., Liu X., Horvath S., Shintaku P.I., Thomas G.V., Said J.W., Reiter R.E. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J. Urol. 2004, 171:1117-1121.
17. Zhigang Z., Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World J. Surg. Oncol. 2004, 2:13.
18. Zhigang Z., Wenlu S. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate. Prostate 2008, 68:190-199.
19. Barbisan F., Mazzucchelli R., Santinelli A., Scarpelli M., Lopez-Beltran A., Cheng L., Montironi R. Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. Histopathology 2010, 57:572-579.
20. Wright J.L., Lange P.H. Newer potential biomarkers in prostate cancer. Rev. Urol. 2007, 9:207-213.
21. Jain A., Lam A., Vivanco I., Carey M.F., Reiter R.E. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol. Endocrinol. 2002, 16:2323-2337.
22. Center M.M., Jemal A., Lortet-Tieulent J., Ward E., Ferlay J., Brawley O., Bray F. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012, 61:1079-1092.
23. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2005, 29:1228-1242.
24. Cheng L., Montironi R., Bostwick D.G., Lopez-Beltran A., Berney D.M. Staging of prostate cancer. Histopathology 2012, 60:87-117.
25. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., Torhorst J., Mihatsch M.J., Sauter G., Kallioniemi O.P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998, 4:844-847.
26. Mehrazma M., Madjd Z., Kalantari E., Panahi M., Hendi A., Shariftabrizi A. Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray. Fetal Pediatr. Pathol. 2013, 32:192-204.
27. Madjd K.A.Z., Molanae S., Asadi-Lari M. BRCA1 protein expression level and CD44+ phenotype in breast cancer patients. Cell J. (Yakhteh) 2011, 13:155-162.
28. Madjd Z., Spendlove I., Moss R., Bevin S., Pinder S.E., Watson N.F., Ellis I., Durrant L.G. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun. 2007, 7:17.
29. Egevad L., Granfors T., Karlberg L., Bergh A., Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int. 2002, 89:538-542.
30. Mazzucchelli R., Barbisan F., Santinelli A., Lopez-Beltran A., Cheng L., Scarpelli M., Montironi R. Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer. Int. J. Immunopathol. Pharmacol. 2009, 22:755-762.
31. Wang G., Wang Z., Sarkar F.H., Wei W. Targeting prostate cancer stem cells for cancer therapy. Discov. Med. 2012, 13:135-142.
32. Yu C., Yao Z., Jiang Y., Keller E.T. Prostate cancer stem cell biology. Minerva Urol. Nefrol. 2012, 64:19-33.
33. Lawson D.A., Witte O.N. Stem cells in prostate cancer initiation and progression. J. Clin. Invest. 2007, 117:2044-2050.
34. Krishnan S., Diagaradjane P., Cho S.H. Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy. Int. J. Hyperthermia 2010, 26:775-789.